Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.216
Buy
RSI(14)
60.953
Neutral
STOCH(KDJ)(9,3,3)
56.483
Neutral
ATR(14)
2.601
High Vlolatility
CCI(14)
61.563
Neutral
Williams %R
16.759
Overbought
TRIX(12,20)
0.586
Sell
StochRSI(14)
53.117
Buy
Harrow Inc
HROW39.060USD
+0.270+0.70%
Market hours （ET）Quotes delayed by 15 min
1.43BMarket Cap
LossP/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-27Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered undervalued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a very weak market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
8
analysts
Buy
Current Rating
59.829
Target Price
+55.12%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 125.31% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.10.
Undervalued
The company’s latest PE is -139.16, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.63M shares, decreasing 10.09% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 1.95M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.
Financial Health
Currency: USD Updated：2025-08-27The company's current financial score is 7.48, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 47.83M, representing a year-over-year increase of 38.29%, while its net profit experienced a year-over-year increase of 31.07%.
Score
Financials
9.65
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
5.93
Operational Efficiency
7.57
Growth Potential
7.15
Shareholder Returns
7.09
Valuation Dimension
Currency: USD Updated：2025-08-27The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -139.16, which is -69.18% below the recent high of -42.88 and 15.30% above the recent low of -117.87.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 55/690
No Data
Forecast
Currency: USD Updated：2025-08-27The company’s current earnings forecast score is 8.75, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Harrow Inc is 63.00, with a high of 76.00 and a low of 42.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
8
analysts
Buy
Current Rating
59.829
Target Price
+55.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
178
Total
5
Median
8
Average
Company name
Ratings
Analysts
Harrow Inc
HROW
8
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
Amgen Inc
AMGN
33
Eli Lilly and Co
LLY
29
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-27The company’s current price momentum score is 9.47, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 43.02 and the support level at 32.16, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
38.400
Buy
MA10
38.561
Buy
MA20
36.060
Buy
MA50
34.329
Buy
MA100
30.277
Buy
MA200
31.872
Buy
Institutional Confidence
Currency: USD Updated：2025-08-27The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 72.57%, representing a quarter-over-quarter increase of 2.40%. The largest institutional shareholder is Private Capital, holding a total of 1.95M shares, representing 5.26% of shares outstanding, with 10.47% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Opaleye Management Inc.
Baum (Mark L)
BlackRock Institutional Trust Company, N.A.
Kaufman (Daniel)
Braidwell LP
Geode Capital Management, L.L.C.
Boll (Andrew R)
State Street Global Advisors (US)
1
2
Risk Assessment
Currency: USD Updated：2025-08-27The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.15, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.33
VaR
+5.29%
240-Day Maximum Drawdown
+61.38%
240-Day Volatility
+78.24%
Return
Best Daily Return
60 days
+11.35%
120 days
+15.69%
5 years
+54.32%
Worst Daily Return
60 days
-5.33%
120 days
-8.86%
5 years
-36.01%
Sharpe Ratio
60 days
+2.80
120 days
+1.58
5 years
+0.91
Risk Assessment
Maximum Drawdown
240 days
+61.38%
3 years
+71.15%
5 years
+71.15%
Return-to-Drawdown Ratio
240 days
-0.10
3 years
+1.03
5 years
+1.42
Skewness
240 days
+0.24
3 years
+2.15
5 years
+1.92
Volatility
Realised Volatility
240 days
+78.24%
5 years
+72.54%
Standardised True Range
240 days
+5.40%
5 years
+2.61%
Downside Risk-Adjusted Return
120 days
+337.51%
240 days
+337.51%
Maximum Daily Upside Volatility
60 days
+48.48%
Maximum Daily Downside Volatility
60 days
+38.36%
Liquidity
Average Turnover Rate
60 days
+1.45%
120 days
+1.49%
5 years
--
Turnover Deviation
20 days
+27.38%
60 days
-0.19%
120 days
+3.12%
Peers
Currency: USD Updated：2025-08-27Harrow Inc
HROW
6.71 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Zoetis Inc
ZTS
7.56 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.55 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.52 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
ACADIA Pharmaceuticals Inc
ACAD
7.52 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
